Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FORECEE

Financiado

Cerrado

Female cancer prediction using cervical omics to individualise screening and pre...

Female cancer prediction using cervical omics to individualise screening and prevention While prevention of most female specific cancers (ovarian, breast, endometrial) has not progressed substantially in recent years, significant progress has been made with cervical cancer due to accessibility of the cell of origin (... ver más

29/02/2020

UNIVERSITY COLLEGE...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 16 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-02-29

PHC-05-2014: Health promotion and disease preven...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

UNIVERSITY COLLEGE LONDON

3.89M€ | Lider

GALLETAS SIRO

580.57K€ | Participante

ERASMUS MC

557.87K€ | Participante

MPG

248.99K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EpiPrecise Epigenetic profiling of menstrual blood for precision cancer... 150K€ Cerrado

VALID-SCREEN Validation of PreCursor M for enhanced Cervical Pre Cancer... 3M€ Cerrado

MEsHH DNA MEthylation for HPV related disease among women living w... 158K€ Cerrado

SixthSense Early diagnosis of cervical cancer through the validation of... 71K€ Cerrado

EPI-FEM-CARE EPIGENETICS FOR FEMALE PERSONALIZED CANCER CARE 8M€ Cerrado

SAF2010-21165 ANALISIS GENOMICO DEL CANCER FAMILIAR MEDIANTE SECUENCIACION... 97K€ Cerrado

Duración del proyecto: 59 meses Fecha Inicio: 2015-03-27
Fecha Fin: 2020-02-29

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto While prevention of most female specific cancers (ovarian, breast, endometrial) has not progressed substantially in recent years, significant progress has been made with cervical cancer due to accessibility of the cell of origin (cervical smear) and availability of a test for the causal agent (human papilloma virus); together these enable identification of high risk individuals and interventions to prevent infection or halt progression to invasive cancer. Our consortium has developed an exciting opportunity to utilise clinically abundant cervical cells in tandem with a multi-omics enabled (genome, epigenome, metagenome) analysis pipeline to understand an individual’s risk of developing a female specific cancer and to direct a personalised screening and prevention strategy. Cervical cells – currently collected within cervical cancer screening – provide an ideal window into other female specific cancers because they are (i) an excellent non-invasive source of high quality DNA, (ii) provide a readout for environmental exposure, (iii) are part of the Müllerian tract and (iv) are hormone sensitive, recording (via the epigenome) various hormonal conditions over a lifetime that trigger cancer development. The FORECEE project is aligned with the novel concept of P4 Medicine (predictive, preventive, personalized, and participatory): it aims to translate the risk prediction tool’s output into personalised recommendations for screening and prevention of female cancers. Our consortium comprises a multi-disciplinary team of experts in clinical oncology, risk-benefit communication, omics technologies, decision analysis, health economics and public health. We will examine the effectiveness of the proposed cervical cell omics analysis method and investigate the legal, social, ethical and behavioural issues related to implementation of the risk prediction tool, through direct interaction with stakeholder groups, to ensure its rapid translation into clinical practice across Europe.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores